Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 3Phase EARLY_PHASE1 1Phase 3 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Recurrence 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Burkitt Lymphoma 1

Interventions

Rituximab 66Cyclophosphamide 46Vincristine 40Doxorubicin 40Prednisone 35Etoposide 19Radiotherapy 14Gemcitabine 13Peripheral Blood Stem Cell Transplantation 12Filgrastim 12Cytarabine 12Lenalidomide 11Carmustine 10VAP-cyclo protocol 9Prednisolone 9Oxaliplatin 9Melphalan 9Methotrexate 7Ifosfamide 7Mitoxantrone 6Bleomycin 6polatuzumab vedotin 5R-CHOP protocol 4Methylprednisolone 4Injections 4Granulocyte Colony-Stimulating Factor 4Cyclosporine 4Cisplatin 4Carboplatin 4pegfilgrastim 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Lymphoma, Large B-Cell, Diffuse × tisagenlecleucel × Clear all
NCT04094311 2026-04-20

Study of Out of Specification for Tisagenlecleucel

Novartis

Phase 3 Recruiting
200 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡